Regeneron Pharmaceuticals Stock Return On Equity
REGN Stock | USD 900.16 3.34 0.37% |
Regeneron Pharmaceuticals fundamentals help investors to digest information that contributes to Regeneron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Regeneron Stock. The fundamental analysis module provides a way to measure Regeneron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regeneron Pharmaceuticals stock.
Last Reported | Projected for Next Year | ||
Return On Equity | 0.15 | 0.16 |
Regeneron | Return On Equity |
Regeneron Pharmaceuticals Company Return On Equity Analysis
Regeneron Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Regeneron Pharmaceuticals Return On Equity | 0.16 |
Most of Regeneron Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regeneron Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Regeneron Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Regeneron Pharmaceuticals is extremely important. It helps to project a fair market value of Regeneron Stock properly, considering its historical fundamentals such as Return On Equity. Since Regeneron Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regeneron Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regeneron Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Regeneron Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Regeneron Pharmaceuticals has a Return On Equity of 0.1626. This is 100.68% lower than that of the Biotechnology sector and 100.45% lower than that of the Health Care industry. The return on equity for all United States stocks is 152.45% lower than that of the firm.
Regeneron Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regeneron Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics of similar companies.Regeneron Pharmaceuticals is currently under evaluation in return on equity category among related companies.
Regeneron Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Regeneron Fundamentals
Return On Equity | 0.16 | ||||
Return On Asset | 0.0849 | ||||
Profit Margin | 0.30 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 88.32 B | ||||
Shares Outstanding | 107.94 M | ||||
Shares Owned By Insiders | 2.58 % | ||||
Shares Owned By Institutions | 89.28 % | ||||
Number Of Shares Shorted | 1.42 M | ||||
Price To Earning | 15.51 X | ||||
Price To Book | 3.82 X | ||||
Price To Sales | 7.57 X | ||||
Revenue | 13.12 B | ||||
Gross Profit | 7.02 B | ||||
EBITDA | 4.05 B | ||||
Net Income | 3.95 B | ||||
Cash And Equivalents | 7.02 B | ||||
Cash Per Share | 65.75 X | ||||
Total Debt | 2.7 B | ||||
Debt To Equity | 0.13 % | ||||
Current Ratio | 5.36 X | ||||
Book Value Per Share | 242.47 X | ||||
Cash Flow From Operations | 4.59 B | ||||
Short Ratio | 3.19 X | ||||
Earnings Per Share | 34.80 X | ||||
Price To Earnings To Growth | 1.46 X | ||||
Target Price | 1048.72 | ||||
Number Of Employees | 13.45 K | ||||
Beta | 0.14 | ||||
Market Capitalization | 98.44 B | ||||
Total Asset | 33.08 B | ||||
Retained Earnings | 27.26 B | ||||
Working Capital | 16.06 B | ||||
Current Asset | 2.92 B | ||||
Current Liabilities | 811.16 M | ||||
Net Asset | 33.08 B |
About Regeneron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regeneron Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Regeneron Pharmaceuticals Piotroski F Score and Regeneron Pharmaceuticals Altman Z Score analysis. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.8 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.